NCT00416351 · OUTCOME

Maximum Tolerated Dose

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment · Source last updated 2022-05-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg/m2 of clofarabine
Interval / dispersion: Not reported
Time frame: 2 years

Groups in this outcome

Clofarabine

Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels. clofarabine

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Clofarabine	29

Reported measurements

Source class 1

Values in mg/m2 of clofarabine · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Clofarabine	20	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
20

denoms

counts
group Id
OG000
value
29
units
Participants

groups

description
Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels. clofarabine
id
OG000
title
Clofarabine

param Type

NUMBER

reporting Status

POSTED

time Frame

2 years

title

Maximum Tolerated Dose

type

PRIMARY

unit Of Measure

mg/m2 of clofarabine

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice